
MSLE Stock Forecast & Price Target
MSLE Analyst Ratings
Bulls say
Satellos Bioscience is a promising company with a strong financial position, reporting no revenue in 1Q26 but with a reported net loss of only $0.53 per share compared to the consensus estimated net loss of $0.68 per share. Additionally, the company's cash and cash equivalents and short-term investments of approximately $69.9M are expected to fund planned operations through 2027, providing a secure base for their drug development program and potential future success. These financials, combined with their focus on developing a novel therapeutic drug for Duchenne muscular dystrophy, make Satellos Bioscience an attractive investment opportunity with potential for growth in the long term.
Bears say
Satellos Bioscience is a relatively new and small company with limited financial resources, making it a risky investment. The company's main program is focused on a single drug for Duchenne muscular dystrophy, leaving them vulnerable to setbacks and competition from larger biotech companies with more diverse pipelines. Additionally, the company has yet to generate significant revenue and its cost of sales is expected to remain high as they continue with drug development efforts.
This aggregate rating is based on analysts' research of Satellos Bioscience Inc and is not a guaranteed prediction by Public.com or investment advice.
MSLE Analyst Forecast & Price Prediction
Start investing in MSLE
Order type
Buy in
Order amount
Est. shares
0 shares